Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 44 Pages
|Risperdal(精神分裂症治療藥):市場預測與分析 Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022|
|出版日期: 2014年02月28日||內容資訊: 英文 44 Pages||
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.
Risperdal (risperidone; Janssen) is a potent 5-HT2A/D2 receptor antagonist, with a higher relative affinity for 5-HT2A over D2 and D3 receptors. Risperdal was first approved by the FDA in 1993 and was the first antipsychotic approved after clozapine. After establishing a solid claim of the atypical antipsychotics market throughout the late 1990s and early 2000s, the development of long-acting injectable Risperdal Consta has helped the brand survive patent expirations to older formulations.